United Therapeutics
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso (treprostinil) in patients with idiopathic pulmonary fibrosis (IPF) was a resounding success. The news sent shockwaves through the financial markets, propelling
